• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks

    NeuroMetrix Reports Publication of Randomized Controlled Trial of Quell Wearable Pain Relief in Chronic Low Back Pain

    Gabrielle Lakusta
    Jan. 23, 2019 08:38AM PST
    Medical Device Investing

    NeuroMetrix (Nasdaq:NURO) reported publication of results from a randomized controlled trial of Quell in subjects with chronic low back pain in the journal Pain Practice. As quoted in the press release: The paper is titled “Outcome of a High Frequency Transcutaneous Electrical Nerve Stimulator (hfTENS) Device for Low Back Pain: A Randomized Controlled Trial.”  The study …

    NeuroMetrix (Nasdaq:NURO) reported publication of results from a randomized controlled trial of Quell in subjects with chronic low back pain in the journal Pain Practice.

    As quoted in the press release:

    The paper is titled “Outcome of a High Frequency Transcutaneous Electrical Nerve Stimulator (hfTENS) Device for Low Back Pain: A Randomized Controlled Trial.”  The study was conducted by Dr. Robert Jamison and colleagues at the Brigham and Women’s Hospital Pain Management Center in Boston, MA.

    The study was a three-month single site, controlled, randomized clinical trial. A total of 68 adult patients with a primary complaint of chronic low back pain were enrolled and randomized with equal probability to treatment with the Quell device (experimental group) or “treatment-as usual” (control group).  Study subjects averaged 46.2 ± 12.7 years of age and 60% were female.  All subjects reported chronic low back pain as their primary complaint.  Over half of the subjects (57%) reported multi-site pain.  All subjects used a smartphone app developed by the Pain Management Center that helps patients document and manage their pain.  Outcome measures included the Brief Pain Inventory, the Pain Catastrophizing Scale, the Pain Disability Index and the Hospital Anxiety and Depression Scale.  All subjects were given Quantitative Sensory Testing at baseline.

    Click here to read the full press release.

    nasdaq:nuro
    The Conversation (0)

    Go Deeper

    AI Powered
    Doctor looking into a microscope

    5 Small Medical Device Companies

    Abbott Introduces NeuroSphere Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.

    Abbott Introduces NeuroSphere Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×